MDxHealth SA (NASDAQ:MDXH) Short Interest Up 2,794.0% in July

MDxHealth SA (NASDAQ:MDXH) saw a large increase in short interest during the month of July. As of July 15th, there was short interest totaling 956,179 shares, an increase of 2,794.0% from the June 30th total of 33,040 shares. Based on an average trading volume of 662,840 shares, the short-interest ratio is currently 1.4 days. Approximately 2.0% of the company’s shares are short sold.

Institutional Trading of MDxHealth

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Intesa Sanpaolo Wealth Management bought a new stake in MDxHealth in the fourth quarter valued at $36,000. Lido Advisors LLC purchased a new stake in shares of MDxHealth in the 3rd quarter worth about $48,000. Citadel Advisors LLC lifted its position in shares of MDxHealth by 30.6% in the 3rd quarter. Citadel Advisors LLC now owns 48,938 shares of the company’s stock worth $228,000 after purchasing an additional 11,456 shares during the period. Jefferies Financial Group Inc. bought a new stake in shares of MDxHealth during the 3rd quarter valued at about $53,000. Finally, Squarepoint Ops LLC bought a new stake in shares of MDxHealth during the 4th quarter valued at about $51,000.

MDxHealth Stock Performance

Shares of NASDAQ MDXH traded down $0.01 during trading hours on Friday, hitting $0.41. The company’s stock had a trading volume of 389,406 shares, compared to its average volume of 457,151. The stock has a market cap of $20.30 million, a price-to-earnings ratio of -0.63 and a beta of 1.43. MDxHealth has a 12 month low of $0.40 and a 12 month high of $5.33. The business has a 50-day simple moving average of $0.57 and a 200-day simple moving average of $2.12.

MDxHealth (NASDAQ:MDXH) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The company had revenue of $23.90 million during the quarter, compared to the consensus estimate of $30.89 million. On average, equities research analysts forecast that MDxHealth will post -0.6 EPS for the current year.

Analysts Set New Price Targets

MDXH has been the topic of several recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th. Lake Street Capital lowered their price objective on MDxHealth from $9.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. BTIG Research dropped their price objective on MDxHealth from $7.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, May 14th. Wall Street Zen cut shares of MDxHealth from a “hold” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $1.50 target price (down from $7.00) on shares of MDxHealth in a research note on Thursday, May 14th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, MDxHealth currently has an average rating of “Hold” and an average target price of $3.50.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.